Stakeholder Response Form
CRG Product Testing

Please complete one response form per consultation document that you wish to provide comments on.

Date	**14/05/18**
Respondent's Name	Jeanette Dickson, Vice President, Faculty of Clinical Oncology
Respondent's Organisation	The Royal College of Radiologists
Replying on behalf of organisation?	Yes
Document responding to:	Clinical Commissioning Policy Proposition: Stereotactic ablative radiotherapy small and non-small cell lung cancer (excluding early stage non-small cell lung cancer patients not suitable for surgery)
Relevant CRG	Radiotherapy Clinical Reference Group

It is proposed that highly specialised products will go for period of public consultation. Please select the consultation level that you consider to be most appropriate.
1 - changes that could reasonably be expected to be broadly supported by stakeholders - up to 6 week consultation

Do you have any further comments on the proposed changes to the document?
1. YES

If Yes, please describe below, in no more than 500 words, any further comments on the proposed changes to the document as part of this initial 'sense check'.
We do acknowledge the evidence base does not currently support widening the indications for SABR in NSCLC and SCLC. However, given that this is an area where considerable trial activity is ongoing - indeed the commissioners acknowledge that relevant evidence is likely to be published shortly – we would urge that data be further scrutinised within a short time frame. One further comment relates to the description of the management of SCLC in limited stage. The wording here is slightly misleading as the evidence base supports concurrent chemoradiotherapy as the gold standard therapy. See NICE CG121: https://www.nice.org.uk/guidance/cg121/chapter/1-Guidance#diagnosis-and-staging

Please declare any conflict of interests relating to this document or service area.